Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection?

The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has been declared a pandemic by the WHO that claimed the lives of thousands of people within a few months. Cancer patients represent a vulnerable population due to the acquired immunodeficiency associated with anti-cancer therapy. Immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kattan, Joseph, Kattan, Clarisse, Assi, Tarek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2020
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161588/
https://www.ncbi.nlm.nih.gov/pubmed/32290754
http://dx.doi.org/10.2217/imt-2020-0077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161588/
https://www.ncbi.nlm.nih.gov/pubmed/32290754
http://dx.doi.org/10.2217/imt-2020-0077

Ejemplares similares